Market Cap 828.67M
Revenue (ttm) 0.00
Net Income (ttm) -3.35M
EPS (ttm) N/A
PE Ratio 6.20
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.72
Volume 1,280,700
Avg Vol 1,042,136
Day's Range N/A - N/A
Shares Out 72.00M
Stochastic %K 66%
Beta 2.53
Analysts Strong Sell
Price Target $43.67

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
DragonAlgo
DragonAlgo Apr. 10 at 9:03 AM
🐉 $OMER CALL — DragonAlgo® Signal Contract: OMER CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.50 Stop: $0.36 TP1: $0.65 TP2: $0.85 TP3: $1.20 🔗 https://dragonalgo.com
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 8:53 AM
$OMER Drug 1 omidria 126 million upfromt licensing deal rayner Drug 2 zaltenibart 240 million upfront with $NVO 2.1 BILLION DEAL global rights buy they kept rights to the tech he created the patent Omeros retains rights to its MASP-3 small-molecule program unrelated to zaltenibart, including the ability to develop and commercialize small-molecule MASP-3 inhibitors with limited restrictions on indications. Omeros also retains rights to its “grandfathered” MASP-3 antibodies, with temporal and indication restrictions on commercialization and for use in advancing its small-molecule therapeutics Drug 3 Omeros Announces First Commercial Sales of YARTEMLEA® 36K a dose 8 to 10 doses going global 4TH OncotoX-AML is an engineered biologic designed to selectively kill both AML blasts (abnormal myeloid cells) and relapse-related leukemia stem cells
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 8:36 AM
$OMER holding the highs comfortably could be interesting going into today. Folks forget this company created OMODRIA FOR CATARACT SURGERY license it to rayner. They're paying on net sales billion paid 126 million upfront https://youtu.be/GOErvjDe-rk?si=rPaqIM0dE5mPAlH0 Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical Omeros received approximately $126 million in cash at closing. In addition, Omeros retains and is entitled to collect the full amount of its accounts receivable outstanding as of today’s closing. Omeros also is eligible to receive an additional $200 million in a commercial milestone payment. Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1.X billion. https://rayner.com/us/
0 · Reply
BiotekInvestor
BiotekInvestor Apr. 10 at 5:15 AM
0 · Reply
Tyler1100
Tyler1100 Apr. 10 at 2:37 AM
$OMER the overnight looks like a promising set up, would love to see it deliver tomorrow 📬 🤑
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 1:35 AM
$OMER must watch Check out this video, "omeros" https://share.google/06y7cFzITImE0pMIo
0 · Reply
CoderTrader
CoderTrader Apr. 9 at 11:01 PM
$OMER nice hits on the way up here! Let’s see it break $12 tomorrow
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 10:35 PM
$OMER looks ready again
0 · Reply
4Reel
4Reel Apr. 9 at 8:03 PM
$OMER close at high of day 💪💪🤙🤙 woooooo
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 8:01 PM
$OMER remember folks if i post it i source it.
1 · Reply
Latest News on OMER
Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 27, 2026, 9:00 AM EST - 2 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®


Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 6:50 PM EST - 3 months ago

Omeros prices transplant complication drug at $36,000 per dose


Gold Edges Lower; Omeros Shares Jump

Dec 24, 2025, 12:21 PM EST - 3 months ago

Gold Edges Lower; Omeros Shares Jump

AAAU BAR DBP GLD GLDM IAU OUNZ


Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 4:11 PM EST - 5 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results


Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:02 PM EDT - 8 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results


Omeros Corporation Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 11 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results


Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 1 year ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight


DragonAlgo
DragonAlgo Apr. 10 at 9:03 AM
🐉 $OMER CALL — DragonAlgo® Signal Contract: OMER CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.50 Stop: $0.36 TP1: $0.65 TP2: $0.85 TP3: $1.20 🔗 https://dragonalgo.com
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 8:53 AM
$OMER Drug 1 omidria 126 million upfromt licensing deal rayner Drug 2 zaltenibart 240 million upfront with $NVO 2.1 BILLION DEAL global rights buy they kept rights to the tech he created the patent Omeros retains rights to its MASP-3 small-molecule program unrelated to zaltenibart, including the ability to develop and commercialize small-molecule MASP-3 inhibitors with limited restrictions on indications. Omeros also retains rights to its “grandfathered” MASP-3 antibodies, with temporal and indication restrictions on commercialization and for use in advancing its small-molecule therapeutics Drug 3 Omeros Announces First Commercial Sales of YARTEMLEA® 36K a dose 8 to 10 doses going global 4TH OncotoX-AML is an engineered biologic designed to selectively kill both AML blasts (abnormal myeloid cells) and relapse-related leukemia stem cells
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 8:36 AM
$OMER holding the highs comfortably could be interesting going into today. Folks forget this company created OMODRIA FOR CATARACT SURGERY license it to rayner. They're paying on net sales billion paid 126 million upfront https://youtu.be/GOErvjDe-rk?si=rPaqIM0dE5mPAlH0 Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical Omeros received approximately $126 million in cash at closing. In addition, Omeros retains and is entitled to collect the full amount of its accounts receivable outstanding as of today’s closing. Omeros also is eligible to receive an additional $200 million in a commercial milestone payment. Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1.X billion. https://rayner.com/us/
0 · Reply
BiotekInvestor
BiotekInvestor Apr. 10 at 5:15 AM
0 · Reply
Tyler1100
Tyler1100 Apr. 10 at 2:37 AM
$OMER the overnight looks like a promising set up, would love to see it deliver tomorrow 📬 🤑
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 1:35 AM
$OMER must watch Check out this video, "omeros" https://share.google/06y7cFzITImE0pMIo
0 · Reply
CoderTrader
CoderTrader Apr. 9 at 11:01 PM
$OMER nice hits on the way up here! Let’s see it break $12 tomorrow
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 10:35 PM
$OMER looks ready again
0 · Reply
4Reel
4Reel Apr. 9 at 8:03 PM
$OMER close at high of day 💪💪🤙🤙 woooooo
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 8:01 PM
$OMER remember folks if i post it i source it.
1 · Reply
CoderTrader
CoderTrader Apr. 9 at 8:00 PM
$OMER some nice slaps EOD!!
0 · Reply
CoderTrader
CoderTrader Apr. 9 at 7:57 PM
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 7:42 PM
$OMER dude is around billions of dollars trustee smead 4.4 billion dollars. Didva 2.1 billion dollar deal for this company $BBBY dumb betting against that guy lemonis My goal is to create a cash offer marketplace, giving folks like @opendoor , @offerpad and all the other cash offer companies a chance to see over 100 million customers and give them the best price. Our job is to advocate for our consumers and we’re going to create a marketplace for people are going to bid for their business. Then everybody wins. Our customers get the highest price their company gets the lowest Caq. We also think that both companies have very unique attributes and different characteristics that can complement our home services business and our finance products and service business. We historically looked at investing in both of them and think they’re both very investable, but it was better for us to remain independent and stand with our customers while creating partnerships with good companies.
0 · Reply
Dollarsforboats
Dollarsforboats Apr. 9 at 7:38 PM
$OMER mucho
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 6:28 PM
$OMER i know way more than i say smead fund is a over 4 billion dollar hedgefund and our capitan is a trustee for years. Wonder if it's a conflict if they buy in. I do my research!! I'd bet on this guy ceo always $JPM did https://fintel.io/i13fs/smead-funds-trust
0 · Reply
WinstonWolfff
WinstonWolfff Apr. 9 at 5:37 PM
$OMER Max pain is 15% lower at 10. Wonder how that will play out in 8 days.
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 5:31 PM
$OMER confidennt in this ceo double surgeon Duke and Stanford Patent list pages of it medical patents 450 issued and pending https://patents.justia.com/inventor/gregory-a-demopulos Hedgefund https://smeadcap.com/smead-funds/ School trustee https://www.evergreenschool.org/our-school/board-of-trustees
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 5:10 PM
$OMER next update should do it for the shorts
0 · Reply
4Reel
4Reel Apr. 9 at 5:07 PM
$OMER trend is up again. Strong earnings outlook is what we are paying for. Sales will be above expectations. And i think 1 or 2 positive PRs by next earnings 💪 patience for that money
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 5:03 PM
$OMER convinced some major shorting going on here
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 4:48 PM
$OMER needs a few more tutes $JPM That news willl tighten things up a bit more JPMorgan Chase & Co. increased its stake in Omeros by 1,201.1% in Q3 to 416,153 shares (0.59% ownership), buying an additional 384,168 shares and valuing the position at about $1.71 million. Analysts are mixed but leaning positive: the consensus rating is a “Moderate Buy” with an average price target of $40.33, and recent upgrades include HC Wainwright raising its target to $40 and Zacks moving to a strong-buy. CAO David J. Borges sold 30,000 shares; insiders own 12.9% and institutions own 48.79% of the stock, which has a market cap of roughly $790.6M and recently reported a surprising quarterly EPS of $3.14 versus an expected (‑$
0 · Reply
CoderTrader
CoderTrader Apr. 9 at 4:44 PM
$OMER it’s go time!
0 · Reply